secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0000950170-24-121069
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics Q3 net loss $96.7M; cash $925.8M; BEAM-101 enrollment at 35 patients
--------------------------------------------------------------------------------

- Net loss $96.7M ($1.17/share) vs $96.1M ($1.22) Q3 2023; R&D $94.3M, G&A $26.5M.
- Cash, equivalents, and marketable securities $925.8M as of Sep 30, 2024; runway into 2027.
- BEACON trial of BEAM-101: 35 patients enrolled, 8 dosed in sickle cell disease; ASH data Dec 2024.
- First cohort dosing complete for BEAM-302 in alpha-1 antitrypsin deficiency; initial data expected 2025.
- ESCAPE platform (BEAM-103/104) nominated for development in SCD and beta-thalassemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024121069/0000950170-24-121069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024121069/beam-20241105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-121069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer